-
Mashup Score: 5
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
Attaining treatment-free remission is a key goal for individuals with early CP #CML, especially for those who achieve a deep molecular remission through TKIs. However, a small percentage of patients maintain a molecular remission of MR4.5 over 3 years. https://t.co/GaQSAXfsaA https://t.co/akVMMEknme
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Ad hoc announcement pursuant to Art. 53 MEDIA & INVESTOR RELEASE Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.
Source: www.novartis.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4FDA Clears IND for TERN-701 for Chronic Myeloid Leukemia - 6 month(s) ago
A phase 1 study will evaluate TERN-701’s safety, efficacy, and pharmacokinetics in a population diagnosed with chronic myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Ponatinib Dose-Ranging Data in Chronic-Phase CML - 6 month(s) ago
Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic - 6 month(s) ago
A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.
Source: www.cancernetwork.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0FDA Clears IND of TERN-701 for Chronic Myeloid Leukemia - 6 month(s) ago
A phase 1 trial of TERN-701 for chronic myeloid leukemia plans to start patient screening in December 2023, with initial data expected to be released in the second half of 2024.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Oncology Best Practice Grand Rounds Series: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer and What You Need to Know - 6 month(s) ago
null
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia - 6 month(s) ago
Leukemia – What is the impact of failing to achieve TKI therapy milestones in chronic myeloid leukemia
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
Attaining treatment-free remission is a key goal for individuals with early CP #CML, especially for those who achieve a deep molecular remission through TKIs. However, a small percentage of patients maintain a molecular remission of MR4.5 over 3 years. https://t.co/GaQSAXfsaA https://t.co/akVMMEknme